Safe use of Sunitinib in metastatic non-clear cell renal cell cancer in the setting of human immunodeficiency virus in
Journal of AIDS and HIV Research · 2011
DOI: 10.5897/jahr11.038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of AIDS and HIV Research, 2011. Verfasst von Govender P. S..
Abstract (Originalsprache)
The introduction of targeted therapies has offered the promise of better survival outcomes for patients with metastatic renal cell carcinoma. Sunitinib malate, an oral, multitargeted tyrosine kinase inhibitor, is an important treatment option for patients with metastatic renal cell carcinoma. This case study explores the controversial use of sunitinib in a patient with a non-clear cell variant of renal cell carcinoma, also on treatment with combined antiretroviral treatment for a co-existing human immunodeficiency virus infection. Key words: Sunitinib, non-clear cell metastatic renal cell carcinoma, human immunodeficiency virus and antiretroviral treatment.
Zitieren
APA
S., G. P. (2011). Safe use of Sunitinib in metastatic non-clear cell renal cell cancer in the setting of human immunodeficiency virus in. Journal of AIDS and HIV Research. https://doi.org/10.5897/jahr11.038
Vancouver
S. GP. Safe use of Sunitinib in metastatic non-clear cell renal cell cancer in the setting of human immunodeficiency virus in. Journal of AIDS and HIV Research. 2011. doi:10.5897/jahr11.038
BibTeX
@article{S2011,
author = {S., Govender P.},
title = {Safe use of Sunitinib in metastatic non-clear cell renal cell cancer in the setting of human immunodeficiency virus in},
journal = {Journal of AIDS and HIV Research},
year = {2011},
doi = {10.5897/jahr11.038}
}
EUVIMED